Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/OvCa in Relapsed Platinum-Sensitive Ovarian Cancer
NCT03905902Phase 3Withdrawn
- Sponsor
- SOTIO Biotech
- Start
- Aug 2021
- Primary completion
- Aug 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 3 trial of DCVAC/OvCa in ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), sponsored by SOTIO Biotech. Planned start Aug 2021; status: withdrawn.
02
Drugs
DCVAC/OvCa
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03905902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905902.